Pfizer won a $10 billion bidding war for Metsera, beating Danish rival Novo Nordisk, securing access to the U. biotech's experimental obesity drug assets.

Viatris on Thursday beat Wall Street estimates for third-quarter results, driven by strong demand for its branded drugs in China and emerging markets, and raised its forecasts for 2025 profit and ...

Viatris (VTRS) stock in focus as the company beats Street forecasts with Q3 2025 financials amid strong emerging market growth and raises its outlook. Read more here.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about a year. This time, the drug that delivered the positive readout is Tukysa, ...

SIOUX FALLS, S.D. (KELO) — October 7th is a big day for radio listeners in southwest Minnesota. Pipestone’s Mylan Ray signed on the air for the first time on this day 50 years ago. Since then, he’s ...

Pfizer Inc. has re-entered the obesity drug sector by acquiring Metsera, Inc., having successfully outmaneuvered six other bidders. Despite skepticism over Pfizer's recent acquisitions, Metsera's ...

We recently published Top 10 Trending Stocks as Famous Billionaire Predicts Massive AI Stock Rally Before Bubble Burst. Pfizer Inc (NYSE:PFE) is one of the trending stocks. Analysts are getting ...

This is read by an automated voice. Please report any issues or inconsistencies here. President Trump’s deal with Pfizer on drug prices won’t do much for American patients, but it’s great for Pfizer.

Pfizer shares surged 14% over two trading days this past week after joining with Trump’s administration to announce an agreement they positioned as both bolstering U.S. leadership in biopharma ...

WASHINGTON — President Donald Trump and drug manufacturer Pfizer announced a deal Tuesday to lower certain drug prices. The arrangement would bring American drug prices in line with the lowest paid by ...

Proponents of Health and Human Services Secretary Robert F. Kennedy Jr.’s “Make America Healthy Again” (MAHA) agenda are outraged over the Trump administration’s deal with pharmaceutical giant Pfizer, ...